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a b s t r a c t
Activated factor X (FXa) is an important player in the coagulation cascade responsible for thrombin
generation, which is activated during atrial ﬁbrillation. Increasing evidence suggests that FXa inﬂuences
cell signalling in various cell types by activating protease-activated receptors (PARs). It is so far not
known if molecular effects of FXa affect atrial signal transduction. To study the effects of FXa, human
atrial tissue slices were cultivated with FXa up to 24 h. Additionally, rapid pacing was applied at 4 Hz to
resemble atrial ﬁbrillation. The inhibitory impact of FXa antagonist (Rivaroxaban), protease-activated
receptor 1 antagonist (SCH79797), and protease-activated receptor 2 antagonist (GB83) were analysed
under experimental conditions. The exposure of atrial tissue to FXa resulted in the 1.7 fold upregulation
of PAR2-mRNA, activation of MAP kinases (ERK1/2) and NF-κB signalling. Furthermore FXa increased the
expression of adhesion molecule ICAM-1 (1.8270.20), chemokine IL-8 (1.9470.20), as well as
prothrombotic molecule PAI-1 (1.5270.17). The combination of rapid pacing and FXa caused signiﬁcant
upregulation of PAR1 (2.8270.22), PAR2 (2.6670.40), ICAM-1 (2.1370.25), IL-8 (2.2270.24), LOX-1
(2.5970.35), and PAI-1 (2.6570.52) at the mRNA level. Rivaroxaban and GB83 prevented upregulation
of PARs, ICAM-1, LOX-1, IL-8, and activation of MAP kinases. The elevation in the expression of PAI-1 was
hindered in the presence of SCH79797, or Rivaroxaban. The present study indicates that FXa mediates
inﬂammatory signalling in atrial tissue. Importantly, FXa and tachyarrhythmia act synergistically to
increase expression of protease-activated receptors and inﬂammatory mediators. Rivaroxaban prevented
effectively FXa-induced molecular effects in human atrial tissue particularly during rapid pacing.
& 2013 The Authors. Published by Elsevier B.V.
1. Introduction
Atrial ﬁbrillation is the most common cardiac arrhythmia. Its
incidence and prevalence constantly rise with age. Atrial ﬁbrilla-
tion not only impairs quality of life, but also increases mortality
due to its attributed stroke risk and heart failure (Schotten et al.,
2011). Atrial ﬁbrillation is a major contributor to ischaemic stroke
at all ages (about 30%) due to thrombus formation and embolisa-
tion from the left atrial appendage (Lip, 2011; Watson et al., 2009).
Depending on clinical risk factors like hypertension, age, diabetes
mellitus etc., the individual risk for thromboembolic events varies
from about 2% to 18% per year (Lip, 2011). Recent studies showed
the importance of prothrombotic endocardial changes for the
development of atrial thrombi (Schotten et al., 2011; Watson
et al., 2009; Goette et al., 2008). The initiating mechanism appears
to be an oxidative stress-induced elevated expression of adhesion
molecules, plasminogen-activator inhibitor-1 (PAI-1), and von-
Willebrandt factor (vWF), which allows endocardial recruitment
of inﬂammatory cells and leukocyte-platelet conjugates to the
endothelium of ﬁbrillating atria (Kamiyama, 1998; Hammwöhner
et al., 2007; Bukowska et al., 2008; Dudley et al., 2005). Thus,
therapeutic interventions, which may interfere with these cellular
signalling processes, might be beneﬁcial in patients with atrial
ﬁbrillation.
The activated coagulation factor X (FXa) is a serine protease and
plays a central role in the coagulation cascade linking the extrinsic
and intrinsic pathway. During haemostasis, FXa associated with
FVa and phospholipids forms the prothrombinase complex and
activates prothrombin to thrombin. In addition to its important
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role in the coagulation cascade, increasing evidence shows that
FXa acts as a signalling molecule mediating cellular responses by
activating protease-activated receptors (PARs) (Steinberg, 2005;
Ossovskaya and Bunnet, 2004). Receptor desensitisation studies
with peptide agonists (PAR1 or PAR2) and experiments with
protease-activated receptor 1 – blocking antibodies indicate that
FXa-signalling is mediated by both protease-activated receptors
(McLean et al., 2001).
The activation of protease-activated receptors inﬂuences a
broad range of intracellular pathways, e.g. stimulation of phos-
pholipase C, mobilisation of calcium ions (Bohm et al., 1996;
Shapiro et al., 2000), suggesting that these receptors are capable
of activating Gq signalling. The G protein-coupled receptors tend
to interact within the subtypes. Thus, the response to activation of
protease-activated receptors depends on the G protein couple
formation and effectors repertoire expressed in the cell type
(Trejo, 2003; Macfarlane et al., 2001).
So far, the effect of FXa and its combined effect with rapid
tachyarrhythmia on cellular signal transduction have not been
studied in human atrial tissue. The FXa-related outside-in signal-
ling might be of particular importance in stressed tissues like
ﬁbrillating atrial myocardium. Thereby, FXa could be an additional
factor causing the well-described phenomenon of structural atrial
remodelling in patients with atrial ﬁbrillation.
2. Materials and methods
2.1. Heart tissue samples
Right atrial appendages were obtained from 54 patients under-
going heart surgery for coronary artery bypass graft or mitral/
aortic valve replacement. None had a history of documented
sustained arrhythmias. Treatments were usually stopped 24 h
before surgery. The clinical characteristics are shown in Table 1.
The study conforms to the Declaration of Helsinki and was
approved by the local Ethics Committee. All patients gave written
informed consent to participate in the study.
2.2. Culturing tissue slices and “in vitro” pacing
The atrial tissue slices were prepared in cold, oxygenated (95% O2/
5% CO2) Tyrode buffer using a vibratome (VT1200S; Leica Micro-
systems, Germany). The 350 mm slices were placed on top of
membrane of tissue inserts (0.4 mm Millipore, Germany) and culti-
vated in a Petri dish, which was ﬁlled with serum-free DMEM
medium (Invitrogen, Germany) implemented with 100 nM of
hirudin (Reﬂudan, Pharmion Germany) for up to 24 h in an incubator
(21% O2, 5% CO2, 37 1C).
For stimulation in an electrical ﬁeld, a pair of custom-built carbon
electrodes was submersed at the opposite ends of a Petri dish and
connected to a stimulation unit (GRASS Stimulator) as previously
described (Bukowska et al., 2006). Pacing of the tissue slices was
performed within the serum-free DMEMmedium up to 24 h at 37 1C
at rates of 0.6 and 4.0 Hz. An antagonist of FXa, Rivaroxaban
(provided by Bayer HealthCare, Germany), antagonists of protease-
activated receptor 1 (SCH79797 hydrochloride), and 2 (GB83) (Axon
Medchem, Groningen, Netherlands) were added to the medium 1 h
before the exposure to FXa or the stimulation in the electrical ﬁeld.
The activated human factor X (FXa) was used in the concentration of
50 nM (Dunn, Germany). The viability of human atrial tissue slices
cultured or stimulated in vivo was conﬁrmed using established vital
staining technique (CellTracker Green CMFDA, Invitrogen, Karlsruhe,
Germany) (Bussek et al., 2009). The living slices were incubated for
1–2 h with the ﬁnal concentration of 5 mM dye in serum-free
medium and imaged as stitched mosaic with a ﬂuorescent micro-
scope (Zeiss Axiovert 200 m) using an excitation wavelength ﬁlter of
480/40 nm, a diachroic ﬁlter 505 nm long pass and emission
wavelength between ﬁlter of 535/50 nm. The cellular integrity of
tissue slices was assessed using lactate dehydrogenase (LDH) assay
(Roche Diagnostics, Mannheim, Germany). The enzyme release from
slices into culture mediumwas measured after 24 h of incubation. To
determine the total LDH content, atrial slices were collected, homo-
genised in 1 ml medium with 0.5% triton X-100. The test was
performed according to the manufacturer's instructions.
2.3. Quantitative RT-PCR
Total RNA was isolated from atrial tissue slices using Nucleo
SpinRNAII (Macherey-Nagel, Germany) in combination with TRIzol/
chloroform extraction (Invitrogen, Germany). Reverse transcription
was carried out with 1 mg of each RNA using random primer with
Fermentas kit according to the manufacture's protocol. (Fermentas,
Germany). Quantitative PCR was performed using the iCycler
(BioRad, Munich, Germany). A 25 ml reaction mixture consisted of
1 SensiMix (Quantace, Bioline, UK), 1 ml cDNA, and 0.3 mM of the
speciﬁc primers (Table 2). Initial denaturation at 95 1C for 600 s was
followed by 40 cycles with denaturation at 95 1C for 10 s, annealing
at 60 1C for 20 s, and elongation at 72 1C for 20 s. The expression
analyses were carried out according to the ΔΔCT method. Ampliﬁca-
tion speciﬁcity of PCR products was conﬁrmed by melting curve
analysis and agarose gel electrophoresis.
2.4. Western blot analysis
Atrial tissue slices were homogenised in modiﬁed RIPA buffer,
which contained 50mM Tris–HCl (pH 7.5), 100 mM sodium chloride,
5 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100, 10% glycerol,
10 mM potassium dihydrogen orthophoshate, 0.5% nonidet P-40,
1 mM phenylmethylsulfonyl ﬂuoride, 1 mM sodium vanadate, 0.5%
deoxylate, 20 mM sodium ﬂuoride, 20 mM glycerol-2-phosphate, and
a protease inhibitor cocktail (all from Sigma, Heidelberg, Germany).
Table 1
The clinical characteristic of patients.
Patients n¼54
Gender M/F 38/16 [70%/30%]
Age 6979
Body mass index in kg/m3 2974
Hypertension 45 [83%]
Diabetes mellitus 23 [43%]
Hyperlipoproteinemia 43 [80%]
Left ventricular hypertrophy 39 [72%]
Left ventricular ejection fraction 5179%
Previous myocardial infarction 27 [50%]
Coronary heart disease 2.7 70.6
NYHA classiﬁcation 2.3 70.6
Previous thromboembolism/stroke 7 [13%]
History of smoking 31 [57%]
Current smoking 3 [5%]
Therapy
ACE inhibitors 26 [48%]
Angiotensin II receptor antagonists 21 [39%]
Statins 35 [65%]
Beta blockers 36 [67%]
Ca-antagonists 16 [30%]
Nitrate 15 [28%]
Anticoagulants 38 [70%]
Diuretic 25 [46%]
ASA 43 [80%]
Values are mean7SD or n [%]; percentages are calculated according to available
data set. F, female, M, male. ACE, angiotensin-converting enzyme; ASA, acetylsa-
licylic acid; NYHA, New York Heart Association-Classiﬁcation.
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Tissue homogenates were centrifuged at 16,000g for 30min and the
resulting supernatant (total tissue homogenate) was stored at 20 1C
for analysis. Protein samples of 20 mg each were separated by SDS-
PAGE gel electrophoresis and transferred to polyvinylidene ﬂuoride
membranes. The membranes were incubated with primary antibody
against phospho-44/42 ERK (1:1000; Cell Signaling, MA, USA), 44/
42ERK (1:1000, Cell Signaling, MA, USA), phospho-NF-κBp65 (1:1000;
Cell Signaling, MA, USA), ICAM-1 (1:1000, Santa Cruz, USA), PAI-1
(1:300, Santa Cruz, USA), LOX-1(1:1000, R&D Systems, Germany),
PAR2 (1:500, Santa Cruz, USA), ß-actin (1:5000, Santa Cruz, USA),
followed by incubation with an appropriate horseradish peroxidase-
conjugated secondary antibody and detection using enhanced chemi-
luminescence (Pierce, Rockford, USA). The protein expression was
quantiﬁed using AlphaEaseFC software (AlphaImager System, Alpha
Innotech, CA, USA).
2.5. Statistical analysis
All values are expressed as mean7S.E.M. if not indicated
otherwise. Statistical analyses were performed using Origin 8.5
(OriginLab Corporation, USA). A P value of o0.05 was considered
to be statistically signiﬁcant (ANOVA).
3. Results
3.1. Viability of human atrial tissue slices
To study the impact of activated coagulation factor X (FXa) on
human atrial tissue, slices from right appendages were prepared
and cultured up to 24 h. The viability of the culturing or stimulated
in the electrical ﬁeld human slices is demonstrated in Fig. 1.
Moreover, the cellular integrity of atrial slices was monitored by
measurements of lactate dehydrogenase (LDH) under different
study conditions. The LDH leakage during culturing experiments
or stimulation in the electrical ﬁeld was determined as a percen-
tage of the total LDH present in the slices as shown in Fig. 1.
3.2. Activation of ERKs in atrial tissue
Research on the signalling mediated by coagulation factors in
endothelial cells has shown that thrombin and FXa activate
mitogen-activated protein kinases. In a ﬁrst set of experiments,
we analysed the phosphorylation state of ERK kinases in atrial
tissue caused by different concentrations of FXa (Fig. 2A). To
maximise the signal in the presence of 100 nM hirudin, which
inhibits possible effects of thrombin, we decided to use FXa in the
concentration of 50 nM. As shown in Fig. 2B, the concentration
of 1 mM of Rivaroxaban was necessary to attenuate the FXa-
dependent activation of ERK under experimental conditions.
We analysed the phosphorylation state of ERK kinases in atrial
tissue after 2 h of stimulation with FXa and followed up to 24 h.
Fig. 2C illustrated the sustained character of FXa-dependent
activation of ERK kinases, which was diminished effectively by
Rivaroxaban even after 24 h of exposure to FXa. To approach the
condition of atrial ﬁbrillation, we stimulated atrial tissue slices in
the electrical ﬁeld with the frequency of 4 Hz in the presence of
FXa. Under different experimental conditions, GB83, an antagonist
of protease-activated receptor 2, and Rivaroxaban, an antagonist of
FXa, showed similar inhibitory effects on ERK activation (Fig. 2C, D).
An antagonist of protease activated receptor 1, SCH79797 signiﬁ-
cantly prevented the activation of p44-ERK (ERK2).
3.3. Protease-activated receptors in response to FXa and tachypacing
in human atrial tissue
Coagulation factors mediate their action through protease-
activated receptors (PARs). To investigate which of the isoforms
contribute to the FXa-dependent response in atrial tissue, we
exposed atrial slices to FXa for 24 h and analysed changes in the
expression of protease-activated receptor 1 and 2. As illustrated in
Fig. 3B and E, FXa enhanced the expression of protease-activated
receptor 2 at the transcriptional and at the protein level. In
addition, tachypacing and FXa acted synergistically on the expres-
sion of protease-activated receptor 2. However, the combined
stimulation in the electrical ﬁeld with presence of FXa increased
the expression of protease-activated receptor 1 considerably more
than pacing alone (Fig. 3A). Rivaroxaban achieved very similar
effects to protease-activated receptor 2 antagonist (GB83) in
preventing the FXa-dependent increase of the protease-activated
receptor 2 expression (Fig. 3B, C). Interestingly, both antagonists
signiﬁcantly counteracted the tachypacing-dependent induction of
protease-activated receptor 1 expression. In contrast, protease-
activated receptor 1 antagonist, SCH79797 showed high speciﬁcity
toward protease-activated receptor 1 and inﬂuenced the expres-
sion of protease-activated receptor 2 to a lesser extent.
3.4. Activation of NF-κB signalling in atrial tissue
Different inﬂammatory and oxidative effectors cause activation of
kinases, which, in consequence, phosphorylate the transcription
factor subunits, NF-κBp65 and NF-κBp50. The phosphorylation at
Ser-536 of NF-κBp65 enables the release from the inhibitory complex
and moving into the nucleus. In our work we decided to follow this
phosphorylation state to evaluate the activation of NF-κB signalling
after exposure to FXa. As shown in Fig. 4A, Western Blotting analyses
revealed the sustained character of the activation of NF-κBp65 in
atrial tissue. The combined stimulation for 24 h showed a signiﬁcant
increase in the phosphorylation at Ser536 of NF-κBp65 (Fig. 4A lower
panel).
Whereas Rivaroxaban achieved its highest inhibitory effects
toward the NF-κB activation after 2 h exposure to FXa, GB83 pre-
sented prolonged activity (Fig. 3A, B). The antagonist of protease-
activated receptor 1 affected the NF-κB activation to a lesser extent.
3.5. Induction of NF-κB target protein in atrial tissue
The transcription factor NF-κB regulates expression of various
inﬂammatory, prooxidative, and prothrombotic molecules. In this
work, we drew our attention to molecules participating in the
atrial thrombogenicity such as an intracellular adhesion molecule
Table 2
Primer sequences used for real-time PCR.
Gene GenBank accession
number
Primer sequence
PAR1 M62424 Forward AAGTCAGGAGAGAGGGTGAAGC
Reverse GATCTAAGGTGGCATTTGTTGC
PAR2 NM_005254 Forward CACCATCCAAGGAACCAATAG
Reverse AATTGGAAGGAAGACAGTGGTC
ICAM-1 BC015969.2 Forward AGTCAGTGTGACCGCAGAGG
Reverse CCTGGCACATTGGAGTCTGC
IL-8 NM_000584.3 Forward AGATGTCAGTGCATAAAGACA
Reverse TATGAATTCTCAGCCCTCTTCAAAAA
LOX-1 AF035776 Forward ACAGATCTCAGCCCGGCAACAAGCA
Reverse GGGAGACAGCGCCTCGGACTCTAAAT
PAI-1 NM_000602 Forward ACTGGAAAGGCAACATGACC
Reverse TGACAGCTCTGGATGAGGAG
TM BC035602 Forward CAGAGCCAACTGCGAGTACC
Reverse CACAGTCGGTGCCAATGTGG
ß-actin NM_001101 Forward AAGATGACCCAGATCATGTTTGAG
Reverse AGGAGGAGCAATGATCTTGATCTT
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(ICAM-1), interleukin-8 (IL-8), plasminogen activator inhibitor
(PAI-1), and receptor for oxidised LDL (LOX-1).
The expression of ICAM-1 was upregulated in response to FXa at
transcriptional and protein level (Fig. 4A, C, D). The additional
exposure of atrial tissue slices to 4 Hz in an electrical ﬁeld resulted
in a signiﬁcant increase in ICAM mRNA and protein contents. GB83
offered the highest inhibitory effect on ICAM induction even after
24 h of exposure to FXa. The protective effects of Rivaroxaban were
highest after 2 h exposure to FXa and lowered with time particularly
under resting condition. SCH79797 affected the ICAM-expression to a
less extent.
Atrial tissue slices responded to FXawith a signiﬁcantly increase in
IL-8 transcriptional level. The rapid pacing acted synergistically on IL-
8 expression. All applied antagonists prevented the induction of IL-8
mRNA signiﬁcantly (Fig. 4E).
The expression of LOX-1, a prooxidative marker, remained
unchanged after exposure to FXa (Fig. 5). However, this expression
was increased 2.5-fold on the mRNA and protein level with addition
of rapid pacing. Interestingly, Rivaroxaban as well as antagonists of
protease-activated receptors 1 and 2 signiﬁcantly prevented upregu-
lation in the LOX-1 expression.
The exposure of atrial tissue slices to FXa for 24 h as well as to
stimulation in the electrical ﬁeld affected the expression of prothrom-
botic molecules, PAI-1 at mRNA and protein level (Fig. 6). The
combination of rapid electrical stimulation with administration of
FXa synergistically increased the expression of PAI-1 (Fig. 6B, C).
Interestingly, the antagonist of protease-activated receptor SCH79797
and Rivaroxaban offered the highest inhibitory effects on PAI-1
expression under all experimental conditions. In this case, antagonist
of protease-activated receptors 2 prevented the FXa-induced expres-
sion of PAI-1 to a lesser degree. The inhibitory effects of the speciﬁc
antagonist of protease-activated receptor 1 on PAI-1 expression strong
imply an involvement of this receptor in mediation of the FXa-
signalling.
In contrast to PAI-1, the expression anti-thrombotic molecule
thrombomodulin was neither affected by FXa nor by rapid
pacing. Rivaroxaban had no effect on thrombomodulin (data
not shown).
Fig. 1. Viability of tissue slices. Representative stitched image of 350 mm thick human slices from right appendages stained with CellTracker green after 24 h of culturing (A),
and after 24 h stimulation in the electrical ﬁeld (B). The integrity of atrial slices was expressed by LDH leakage during culturing (C) or stimulation in the electrical ﬁeld.
(D) The LDH leakage was determined as a percentage of the total LDH present in the slices. Results are mean7standard deviation at least 4 experiments. Scale bar: 1000 mm.
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4. Discussion
The present study provides evidence that FXa acts as a mediator
of inﬂammatory signalling in human atrial tissue. Moreover, we
describe FXa effects in a model of atrial tachyarrhythmia. We can
show that application of FXa and atrial tachyarrhythmia act
synergistically to increase myocardial expression of protease-
activated receptors, followed by activation of MAP kinase pathway
(ERK1/2) and NF-κB pathway. As a result, expression of inﬂamma-
tory molecules: IL-8, ICAM-1, and endothelial factors like proox-
idative LOX-1 and prothrombotic PAI-1 are upregulated. We have
shown that blockade of FXa by Rivaroxaban abolished FXa- and
tachycardia-induced remodelling process in atrial tissue. Further-
more, protease-activated receptors have emerged as powerful
targets for preventing molecular changes in atrial tissue.
FXa mediates cellular signalling via protease-activated receptor
1, or protease-activated receptor 2, or both, depending on cell type
and cofactor expression. In fact, studies on dermal ﬁbroblasts and
endothelial cells have demonstrated that FXa induced secretion of
cytokines via activation of both receptors (Senden et al., 1998;
Bachli et al., 2003). However, in lung ﬁbroblasts, protease-
activated receptor 1 played a dominant role in FXa-induced
responses (Scotton et al., 2009). In contrast, in human vascular
smooth muscle cells (SMCs), FXa (50 nM) increased only transcrip-
tional expression of protease-activated receptor 2 (Jobi et al.,
2011). Moreover, Jobi et al. (2011) demonstrated that FXa pro-
moted PAR2 mRNA stabilisation through increased human antigen
R/PAR2 mRNA binding. The effects of FXa on the atrial tissue have
not been investigated previously. Our study revealed that
the exposure of resting atrial slices to FXa resulted in an increase
in transcriptional expression of protease-activated receptor 2.
In contrast, FXa alone had no speciﬁc effect on the transcript-
ional expression of protease-activated receptor 1. However, the
regulatory impact of the speciﬁc antagonist of protease-activated
Fig. 2. Activation of ERK in the response to stimulation with FXa and pacing. The phosphorylation state of ERK was analysed using Western blots. (A) FXa activated ERK in a
concentration-dependent manner. Human atrial slices were cultivated with different FXa concentrations for 2 h. The immunoblot is representative of two independent
experiments. (B) Inhibition of FXa-dependent ERK activation by Rivaroxaban (Riva). Human atrial slices were preincubated with 0.1 and 1 mM Riva for 1 h before the exposure
to 50 nM FXa for an additional 2 h. The immunoblot is representative of three independent experiments. (C) Activation of ERK in the response to FXa. Human atrial slices
were exposed to 50 nM FXa without or with 1 mM Riva for 2 h (n¼6 vs. CTL), and to 50 nM FXa for 24 h without (n¼10) or with 1 mM Riva (n¼7 vs. CTL), or 10 mM SCH (n¼3
vs. CTL), or 10 mM GB83 (n¼3 vs. CTL). (D) Activation of ERK in the response to pacing and FXa. Atrial slices were paced at 4 Hz in the presence of 50 nM FXa (n¼10 vs.
0.6 Hz) and in the presence of FXa and 1 mM Riva (n¼5 vs. 4.0 HzþFXa), or 10 mM SCH (n¼5 vs. 4.0 HzþFXa), or 10 mM GB83 (n¼5 vs. 4.0 HzþFXa) for 24 h. Further
experiments were done to analyse the effect of rapid pacing alone (n¼4 vs. 0.6 Hz). (E) Quantiﬁcation of phospho-ERK protein contents by densitometric analysis of Western
blots. Results are expressed as means7S.E.M, compared to unpaced control (CTL), or 0.6 Hz control for pacing experiments respectively. nPo0.01, #Po0.05, and §P¼0.07.
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receptor 1 on the PAI-1 and IL-8 expression, strong suggested an
involvement of receptor type 1 in the cellular response to FXa. Of
note, atrial tachyarrhythmia per se induced upregulation of
protease-activated receptor 1 at mRNA level. Interestingly, the
combined stimulation with tachyarrhythmia and FXa caused
synergistic upregulation of protease-activated receptors at the
transcriptional level. This association between tachycardia and
the elevated expression of protease-activated receptor has not
been investigated so far.
The ERK–MAPK activation is used as a marker of activation of
protease-activated receptors (Ossovskaya and Bunnett, 2004) and is
accompanied by a wide range of PAR-mediated cellular processes
including ﬁbrosis, cellular proliferation, inﬂammatory signalling
(Borensztajn et al., 2009), and hypertrophy (Pawlinski et al., 2007).
Fig. 3. Expression of protease-activated receptors in response to stimulation with FXa and rapid pacing. The expressions of PAR1 (A) and PAR2 (B) were analysed using RT-
PCR. Human atrial slices were exposed to 50 nM FXa for 24 h without (n¼9) or with 1 mM Riva (n¼6 vs. CTL), or 10 mM SCH (n¼3 vs. CTL), or 10 mM GB83 (n¼3 vs. CTL).
Then, atrial slices were stimulated in electrical ﬁeld at 4 Hz in the presence of 50 nM FXa (n¼7 vs. 0.6 Hz) and in the presence of FXa and 1 mM Riva (n¼4 vs. 4 HzþFXa), or
10 mM SCH (n¼3 vs. 4.0 HzþFXa), or 10 mM GB83 (n¼3 vs. 4.0 HzþFXa) for 24 h. In addition, further experiments were done to analyse the effects of rapid pacing alone
(n¼5 vs. 0.6 Hz). Results are expressed as means7S.E.M, compared to unpaced control (CTL), or 0.6 Hz control for pacing experiments respectively. (C) The PAR2 protein
expression was analysed using Western blots. FXa increased PAR2 protein content in the response to FXa (C, upper panel). The immunoblot is representative of two
independent experiments. Rivaroxaban (Riva) inhibits PAR2 protein level in a concentration-dependent manner. Human atrial slices were preincubated with 0.1 and 1 mM
Riva for 1 h before the exposure to 50 nM FXa for an additional 2 h. Increase of PAR2 protein in the response to FXa (C, middle panel). Human atrial slices were exposed to
50 nM FXa for 24 h without or with 1 mM Riva, or 10 mM SCH. (C, lower level) Increase of PAR2 protein in the response to pacing and FXa. Atrial slices were paced at 4 Hz in
the presence of 50 nM FXa and in the presence of FXa and 1 mM Riva, or 10 mM SCH, or 10 mM GB83 for 24 h. The immunoblots are representative of three independent
experiments. nPo0.01, and #Po0.05.
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The increasing evidence has shown that FXa elicits the inﬂammatory
response through the activation of the transcription factor NF-κB
(Riewald and Ruf, 2001; Jiang et al., 2011; Shimizu et al., 2004;
Matsushita et al., 2006). Numerous inﬂammatory genes are regulated
by the NF-κB family of transcription factors including proinﬂamma-
tory cytokines and adhesion molecules (Hoberg et al., 2004). In
human endothelial cells, FXa increases the expression of adhesion
molecules (ICAM-1, VCAM-1) and production of proinﬂammatory
Fig. 4. Activation of NF-κB signalling in the response to stimulation with FXa and rapid pacing. The phosphorylation at Ser-536 of NF-κBp65 and ICAM-1 protein expression
were analysed using Western blots. (A, upper panel) Human atrial slices were exposed to 50 nM FXa without or with Riva for 2 h (n¼6 vs. CTL), and to 50 nM FXa for 24 h
without (n¼10 vs. CTL), and with 1 mM Riva (n¼7 vs. CTL), or 10 mM SCH (n¼3 vs. CTL), or 10 mM GB83 (n¼3 vs. CTL). (A, lower panel) Then, atrial slices were paced at 4 Hz
in the presence of 50 nM FXa (n¼10 vs. 0.6 Hz) and in the presence of FXa and 1 mM Riva (n¼5 vs. 4.0 HzþFXa), or 10 mM SCH (n¼5 vs. 4.0 HzþFXa), or 10 mM GB83 (n¼5
vs. 4.0 HzþFXa) for 24 h. In addition, further experiments were done to analyse the effects of rapid pacing alone (n¼4 vs. 0.6 Hz). Quantiﬁcation of phospho-NF-κBp65
(B) and ICAM-1 (C) protein contents was carried out by densitometric analysis of Western blots. (D, E) Additionally the expression of proinﬂammatory cytokine, IL-8 and
adhesion molecule, ICAM-1 were analysed using RT-PCR after exposition to FXa (n¼9 vs. CTL) and to FXa and pacing (n¼8) after 24 h. Results are expressed as means7S.E.
M, compared to unpaced control (CTL), or 0.6 Hz control for pacing experiments respectively. nPo0.01, #Po0.05, §P¼0.07.
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cytokines (IL-6, IL-8, MCP-1) (Senden et al., 1998). In human SMCs,
FXa causes a dose-dependent induction of IL-6 and tissue factor
expression (McLean et al., 2001). In mouse ﬁbroblast cell line, FXa-
induced ERK1/2 phosphorylation was accompanied by the secretion
of the cytokines, and differentiation into myoﬁbroblasts (Borensztajn
et al., 2009). In our study, we have shown that FXa induced the
inﬂammatory response by activation of ERK1/2 and NF-κB and this
stimulation in atrial tissue resulted in sustained activation (phos-
phorylation) throughout a 24 h period. This result contrasts with
other studies showing a transient character of phosphorylation
events upon exposure to FXa. In our work, we have used tissue
slices composed predominantly of atrial cardiomyocytes and ﬁbro-
blasts that may interplay during the exposure to FXa. A study by
Rauch et al. (2004) reported that FXa released a basic ﬁbroblast
growth factor (bFGF) into pericellular matrix (Rauch et al., 2004). The
autocrine transactivation of FGF receptor-1 resulted in sustained ERK
phosphorylation in vascular SMCs (Rauch et al., 2004; Pratsinis and
Kletsas, 2007), which might implicate the bimodal effect of FXa, in
general. In line with the activation of MAPK and NF-κB signalling in
response to FXa induction, we observed an increase of proinﬂamma-
tory molecule like ICAM-1 and IL-8, and prothrombotic PAI-1 in atrial
tissue. Of importance, our results suggest that application of FXa and
atrial tachyarrhythmia acted synergistically to induce inﬂammatory
and prothrombotic tissue effects. One key element of protease-
activated receptors signalling depends on modulation of calcium
homoeostasis. In support of this hypothesis, a sustained increased
[Ca2þ]i, which depends on extracellular Ca2þ inﬂux, was described
in a subpopulation of the platelets after stimulation with thrombin
plus collagen and was associated with generating procoagulant
platelet surfaces (Keuren et al., 2005). However, further research is
needed to fully elucidate all mechanisms responsible for regulation of
protease-activated receptor signalling.
Naturally and synthetic occurring FXa inhibitors exert strong
anticoagulant activity and have been shown to be potent antith-
rombotic agents in animal models of venous and arterial throm-
bosis (Wong et al., 1996; Perzborn et al., 2007). Independent of the
antithrombotic actions, several studies demonstrated that FXa
inhibitors exert anti-inﬂammatory effects (McLean et al., 2001;
Hoberg et al., 2004). DX-9065a, the ﬁrst generation of FXa
inhibitors, prevented FXa-induced IL-6 mRNA expression in
human gingival ﬁbroblasts and was considered as a useful drug
for periodontal disease. Recently Zhou et al. (2011) have demon-
strated that long-term administration of Rivaroxaban to apolipo-
protein E-deﬁcient mice reduced the expression of inﬂammatory
mediators in aortic tissue (Zhou et al., 2011).
Cardiac tachyarrhythmia is known to induce signiﬁcant elec-
trophysiological and structural changes in atrial tissue, which
themselves may contribute to the persistence and aggravation of
atrial ﬁbrillation (Schotten et al., 2011; Goette et al., 1996).
Alterations in the intracellular calcium and activation of oxidative
Fig. 5. Induction of LOX-1 in the response to stimulation with FXa and pacing. Human atrial slices were exposed to 50 nM FXa without (n¼10 vs. CTL) and with 1 mM Riva
(n¼7 vs. CTL), or 10 mM SCH (n¼3 vs. CTL), or 10 mM GB83 (n¼3 vs. CTL) for 24 h. Then, atrial slices were stimulated in electrical ﬁeld at 4 Hz in the presence of 50 nM FXa
(n¼10 vs. 0.6 Hz) and in the presence of FXa and 1 mM Riva (n¼5 vs. 4.0 HzþFXa), or 10 mM SCH (n¼5 vs. 4.0 HzþFXa), or 10 mM GB83 (n¼5 vs. 4.0 HzþFXa) for 24 h.
Furthermore, effects of rapid pacing were studied (n¼4, 4 Hz vs. 0.6 Hz). (A) LOX-1 expressionwas analysed using Western blots. (B) Quantiﬁcation of LOX-1 protein contents
by densitometric analysis of Western blots. (C) Quantitative analysis of LOX-1 mRNA expression using RT-PCR. Results are expressed as means7S.E.M, compared to unpaced
control (CTL), or 0.6 Hz control for pacing experiments respectively. nPo0.01, and #Po0.05.
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stress signalling have been identiﬁed to trigger atrial remodelling
during atrial ﬁbrillation (Bukowska et al., 2008; Dudley et al.,
2005, Schild et al., 2006). Recently, we were able to show the
impact of the nuclear factor kappa B (NF-κB) pathway in the
process of rapid pacing induced oxidative stress (Bukowska et al.,
2008). In line with the activation of NF-κB signalling, we observed
an increase in expression of adhesion molecules like ICAM-1, but
also LOX-1 in atrial tissue from patients with atrial ﬁbrillation and
in in vitro paced atrial tissue slices. These ﬁndings strongly imply
that oxidative signalling accounts for endocardial activation fol-
lowed by an increased risk of atrial thrombus formation during
tachyarrhythmia. Endothelial damage and prothrombotic endothe-
lial alteration are present in ﬁbrillating atria (Schotten et al., 2011).
They are a prerequisite for the development of atrial clots, since
atrial thrombi always start to grow from the atrial wall.
5. Study limitations
The present study has several limitations. First off all, the
human tissue slices were prepared from biopsies obtained only
from right appendages. Although pathological alterations might be
more pronounced in left atria, there is no data supporting the
principally different employment of molecular signal cascades
within left and right atria. Second, all patients had coronary artery
or valve disease with concomitant hypertension and/or diabetes
mellitus. Thus, in contrast to animal studies, no healthy controls
were used. Third, our study was limited by inability to perform
measurements of intracellular calcium level in tissue slices during
culturing or stimulation due to technical problems involving the
thickness of the slices and dimension of devices used in our
“in vitro” model. Finally, the high concentration of FXa admini-
strated in “in vitro” experiments might rouse reasonable scepticism
of the “in vivo” relevance. In human plasma, the concentration of
zymogen factor X is 140 nM. Thus, concentration of activated factor
X could theoretically reach high concentration at the sites of local
FXa activation and inﬂuence the intracellular signalling in vivo. The
gene induction required 10 nM of FXa, a concentration consistent
with cell membrane-binding afﬁnity for FXa (Riewald and Ruf,
2001). Obviously, future experiments should elucidate the in vivo
relevance of FXa in atrial arrhythmia.
6. Conclusions
The present study provides evidence that in human atrial
tissue, FXa acts a mediator of inﬂammatory signalling via activa-
tion of protease-activated receptors 1 and 2. Most importantly,
the synergistic action of FXa and atrial tachyarrhythmia results
in a potentiated response involving the increase of inﬂammatory
and oxidative stress molecules, which create an inﬂamma-
tory, prothrombotic status in atrial tissue. Importantly, the FXa
Fig. 6. Effects of the stimulation with FXa and pacing on the expression of PAI-1. (A) PAI-1 protein expression was analysed using Western blots. Human atrial slices were
exposed to 50 nM FXa without (n¼10 vs. CTL) and with 1 mM Riva (n¼7 vs. CTL), or 10 mM SCH (n¼3 vs. CTL), or 10 mM GB83 (n¼3 vs. CTL).for 24 h (A, upper panel). Then,
atrial slices were stimulated in electrical ﬁeld with the frequency of 4 Hz in the presence of 50 nM FXa (n¼ 10 vs. 0.6 Hz) and in the presence of FXa and 1 mM Riva (n¼5 vs.
4.0 HzþFXa), or 10 mM SCH (n¼5 vs. 4.0 HzþFXa), or 10 mM GB83 (n¼5 vs. 4.0 HzþFXa) for 24 h. Furthermore, effects of rapid pacing were analysed (n¼4, 4 Hz vs. 0.6 Hz).
(B) Quantiﬁcation of PAI-1 protein contents was carried out by densitometric analysis. Additionally analysis using RT-PCR were performed to determine the expression of
prothrombotic PAI-1 (C). Results are expressed as means7S.E.M, compared to unpaced control (CTL), or 0.6 Hz control for pacing experiments respectively. nPo0.01, and
#Po0.05, §P¼0.07.
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induced inﬂammatory signalling can be substantially attenuated
by FXa antagonist, Rivaroxaban. Thus, FXa and protease-activated
receptors appear as novel therapeutic targets to prevent atrial
remodelling.
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